Aeterna Zentaris

Weeks after launching Aeterna Zentaris castoff, Strongbridge turns around and sells rights to Novo Nordisk — at a premium
Weeks after launching Aeterna Zentaris castoff, Strongbridge turns around and sells rights to Novo Nordisk — at a premium
Endpoints
Strongbridge
Aeterna Zentaris
Macrilen
Novo Nordisk
adult growth hormone deficiency
Flag link:
Post-review, Aeterna Zentaris strikes commercialization deal
Post-review, Aeterna Zentaris strikes commercialization deal
Biopharma Dive
Aeterna Zentaris
Macrilen
Flag link:
Here's Why AEterna Zentaris Is Soaring Today
Here's Why AEterna Zentaris Is Soaring Today
Insider Financial
Aeterna Zentaris
Macrilen
adult growth hormone deficiency
AGHD
Flag link:
Warring with ex-CEO, options shrinking, Aeterna Zentaris turns to a strategic review
Warring with ex-CEO, options shrinking, Aeterna Zentaris turns to a strategic review
Endpoints
Aeterna Zentaris
David Dodd
Macrilen
Flag link:
Aeterna Zentaris claims it booted CEO and then discovered a plot to grab control of its lead asset
Aeterna Zentaris claims it booted CEO and then discovered a plot to grab control of its lead asset
Endpoints
Aeterna Zentaris
Pharma CEOs
Macrilen
David Dodd
Flag link:
Aeterna Zentaris taps new CEO as it evaluates alternatives
Aeterna Zentaris taps new CEO as it evaluates alternatives
BioPharma Dive
Aeterna Zentaris
Pharma CEOs
Macrilen
Flag link:
Endometrial Cancer Drug Fails in Late-Stage Clinical Trial
Endometrial Cancer Drug Fails in Late-Stage Clinical Trial
Xtalks
endometrial cancer
Aeterna Zentaris
clinical trials
Zoptrex
Flag link:
Aeterna Zentaris shares eviscerated by its latest late-stage drug disaster
Aeterna Zentaris shares eviscerated by its latest late-stage drug disaster
Endpoints
Aeterna Zentaris
clinical trials
Zoptrex
endometrial cancer
Flag link:
Aeterna Zentaris doubles down on macimorelin PhIII, and loses
Aeterna Zentaris doubles down on macimorelin PhIII, and loses
Endpoints
Aeterna Zentaris
macimorelin
clinical trials
growth hormone deficiency
Flag link:
Aeterna Zentaris reports 2Q loss
Aeterna Zentaris reports 2Q loss
Yahoo/AP
Aeterna Zentaris
earnings
Flag link:
Aeterna Zentaris posts 1st-quarter loss of $3.7 million
Aeterna Zentaris posts 1st-quarter loss of $3.7 million
Yahoo/AP
Aeterna Zentaris
earnings
Flag link:
Aeterna Zentaris Announces At the Market Issuance Program
Aeterna Zentaris Announces At the Market Issuance Program
Yahoo
Aeterna Zentaris
market issuance
Flag link:
Top 6 BioPharma Movers of the Week
Top 6 BioPharma Movers of the Week
24/7 Wall St
Anavex
Aeterna Zentaris
Arena Pharmaceuticals
Foamix
Invivo Therapeutics
Zafgen
Flag link:
Aeterna Zentaris Rises on Finalized Marketing Agreement
Aeterna Zentaris Rises on Finalized Marketing Agreement
24/7 Wall St
Aeterna Zentaris
Armune BioScience
Apifiny
prostate cancer
Flag link:
Aeterna Zentaris Announces Restructuring of Finance & Accounting Operations and Closure of Quebec City Office
Aeterna Zentaris Announces Restructuring of Finance & Accounting Operations and Closure of Quebec City Office
Yahoo
Aeterna Zentaris
restructuring
Flag link:
Aeterna Zentaris reports 2Q loss
Aeterna Zentaris reports 2Q loss
Yahoo/AP
Aeterna Zentaris
earnings
Flag link:
Aeterna Zentaris: Final Data for Phase 1 Portion of Ongoing Phase 1/2 Trial with Zoptarelin Doxorubicin in Prostate Cancer Published in Clinical Cancer Research
Aeterna Zentaris: Final Data for Phase 1 Portion of Ongoing Phase 1/2 Trial with Zoptarelin Doxorubicin in Prostate Cancer Published in Clinical Cancer Research
Yahoo
Aeterna Zentaris
prostate cancer
zoptarelin doxorubicin
Flag link:
Aeterna Zentaris bottoms out after a stinging FDA rejection
Aeterna Zentaris bottoms out after a stinging FDA rejection
Fierce Biotech
Aeterna Zentaris
FDA
macimorelin
Flag link:
Aeterna Zentaris announces workforce reduction and optimization program
Aeterna Zentaris announces workforce reduction and optimization program
Yahoo/Fly on the Wall
Aeterna Zentaris
layoffs
Flag link:
AEterna Zentaris: An Interesting Investment With Long-Term Growth Potential
AEterna Zentaris: An Interesting Investment With Long-Term Growth Potential
Seeking Alpha
Aeterna Zentaris
AEZS-130
Flag link:

Pages